Travere Therapeutics Inc (NASDAQ:TVTX)’s traded shares stood at 0.37 million during the latest session, with the company’s beta value hitting 0.74. At the last check today, the stock’s price was $14.34, to imply an increase of 5.04% or $0.69 in intraday trading. The TVTX share’s 52-week high remains $15.36, putting it -7.11% down since that peak but still an impressive 64.3% since price per share fell to its 52-week low of $5.12. The company has a valuation of $1.10B, with an average of 2.24 million shares in intraday trading volume over the past 10 days and average of 1.52 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Travere Therapeutics Inc (TVTX), translating to a mean rating of 1.47. Of 8 analyst(s) looking at the stock, 0 analyst(s) give TVTX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 8 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.67.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
After registering a 5.04% upside in the latest session, Travere Therapeutics Inc (TVTX) has traded red over the past five days. The 5-day price performance for the stock is 2.34%, and 44.39% over 30 days. With these gigs, the year-to-date price performance is 59.49%. Short interest in Travere Therapeutics Inc (NASDAQ:TVTX) saw shorts transact 8.66 million shares and set a 5.94 days time to cover.
The extremes give us $12 and $28 for target low and target high price respectively. As such, TVTX has been trading -95.26% off suggested target high and 16.32% from its likely low.
Travere Therapeutics Inc (TVTX) estimates and forecasts
Looking at statistics comparing Travere Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Travere Therapeutics Inc (TVTX) shares are 103.67% up over the last 6 months, with its year-to-date growth rate higher than industry average at 22.09% against 17.60%. Revenue is forecast to shrink -134.00% this quarter before jumping 51.70% for the next one. The rating firms project that company’s revenue will grow 54.90% compared to the previous financial year.
Revenue forecast for the current quarter as set by 13 analysts is 60.87M. Meanwhile, for the current quarter, a total of 13 analyst(s) estimate revenue growth to 67.21M.Earnings reports from the last fiscal year show that sales brought in 37.09M and 45.06M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 64.10% before jumping 49.20% in the following quarter.
TVTX Dividends
Travere Therapeutics Inc has its next earnings report out on 2024-Nov-05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Travere Therapeutics Inc (NASDAQ:TVTX)’s Major holders
The next major institution holding the largest number of shares is ARMISTICE CAPITAL, LLC with 7.5 million shares, or about 9.6774% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $61.65 million.
We also have Delaware Group Equity Fds V-Small Cap Core Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Travere Therapeutics Inc (TVTX) shares. Going by data provided on May 31, 2024, Delaware Group Equity Fds V-Small Cap Core Fund holds roughly 3.57 shares. This is just over 4.66% of the total shares, with a market valuation of $50.64 million. Data from the same date shows that the other fund manager holds a little less at 2.5, or 3.27% of the shares, all valued at about 35.53 million.
